In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, speaks with Natasha Mesinkovska, MD, about diagnosing and managing alopecia areata (AA) with a focus on JAK inhibitors. Dr Mesinkovska shares diagnostic pearls, including full-body exam essentials, dermoscopy tips, recognition of key comorbidities, and the impact of AA on mental health. They also touch on less common subtypes such as diffuse AA and the ophiasis pattern, as well as the role of the SALT score.The conversation then turns to treatment, with insights into the 3 FDA-approved JAK inhibitors for AA: baricitinib, ritlecitinib, and deuruxolitinib. They discuss mechanisms of action, dosing, boxed warnings, and counseling strategies, while offering guidance on treatment selection and building confidence without head-to-head trial data. The episode closes with a discussion of GLP-1–associated skin considerations that may become increasingly relevant for board exams, along with key points on body contouring procedures that are seeing greater demand as GLP-1 use rises. Tune in to the full episode to sharpen your diagnostic skills, gain confidence in prescribing JAK inhibitors, and stay ahead on emerging board topics in alopecia areata and beyond.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related